63 completed, 10 active not recruiting, 10 terminated, 8 unknown. 101 Phase 3, 12 Phase 2.
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naproxen Versus Placebo as Adjunct Treatment of Cellulitis enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious | Phase 3 | Not yet recruiting | Ottawa Hospital Research Institute | 884 | 2026-11-01 | 2026-10-20 |
| Efficacy of Diloxanide Furoate as Additional Luminal Agent Along With Metronidazole for the Treatment of Amoebic Liver Abscess Diloxanide furoate, Placebo - Liver Abscess, Amoebic Liver Abscess | Phase 3 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 220 | 2026-09-04 | 2026-09-10 |
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Remibrutinib - Hidradenitis Suppurativa | Phase 3 | Recruiting | Novartis Pharmaceuticals | 710 | 2026-07-10 | 2026-10-13 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | Bluefin Biomedicine, Inc. | 210 | 2025-11-03 | 2026-10-14 |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab - Hidradenitis Suppurativa | Phase 3 | Enrolling by invitation | MoonLake Immunotherapeutics AG | 835 | 2025-06-27 | 2026-06-08 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Incyte Corporation | 580 | 2025-06-23 | 2026-07-28 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Incyte Corporation | 573 | 2025-06-12 | 2026-07-08 |
| Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy, Lymecyclin and corresponding placebos of the experimental arm - Hidradenitis Suppurativa | Phase 3 | Recruiting | Institut Pasteur | 92 | 2025-05-22 | 2025-07-09 |
| A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa Bimekizumab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | UCB Biopharma SRL | 43 | 2025-04-07 | 2026-09-25 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 565 | 2025-03-20 | 2026-10-15 |
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Recruiting | Incyte Corporation | 600 | 2025-02-28 | 2026-10-09 |
| Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks, Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks, Standard medical care - Liver Abscess | Phase 3 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 220 | 2025-02-25 | 2025-04-13 |
| Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin - Complicated Appendicitis, Intra-Abdominal Abscess | Phase 3 | Recruiting | Spaarne Gasthuis | 752 | 2025-02-24 | 2026-10-09 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 588 | 2025-01-31 | 2026-10-15 |
| An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) Sonelokimab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 35 | 2024-12-30 | 2026-05-06 |
| A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Lutikizumab, Placebo - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | AbbVie | 1400 | 2024-06-27 | 2026-09-02 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab, Placebo - Hidradenitis Suppurativa | Phase 3 | Completed | MoonLake Immunotherapeutics AG | 422 | 2024-05-15 | 2026-08-12 |
| Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Sonelokimab, Placebo - Hidradenitis Suppurativa | Phase 3 | Completed | MoonLake Immunotherapeutics AG | 418 | 2024-05-14 | 2026-06-08 |
| A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab Spesolimab, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 39 | 2024-05-08 | 2026-06-17 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Active not recruiting | Incyte Corporation | 617 | 2024-01-30 | 2026-08-25 |
Showing 20 of 101. Sign in to see all of them.
Cellulitis (37) · Hidradenitis Suppurativa (33) · Abscess (20) · Skin Diseases (11) · Wound Infection (11) · Hidradenitis (10) · Skin Diseases, Bacterial (10) · Abdominal Abscess (7) · Bacterial Infections (7) · Infections (7) · Surgical Wound Infection (6) · Empyema (5) · Soft Tissue Infections (5) · Empyema, Pleural (4)
Infections (94) · Skin and Connective Tissue Diseases (71) · Skin Diseases, Infectious (66) · Pathological Conditions, Signs and Symptoms (62) · Pathologic Processes (61) · Inflammation (59) · Bacterial Infections and Mycoses (46) · Skin Diseases (39) · Bacterial Infections (38) · Connective Tissue Diseases (37) · Skin Diseases, Bacterial (31) · Sweat Gland Diseases (29) · Hidradenitis (23) · Abscess (11)
Vancomycin (12) · Moxifloxacin (7) · Aztreonam (6) · Linezolid (6) · Adalimumab (4) · Ceftaroline (4) · bimekizumab (4) · sonelokimab (4) · Amoxicillin-Potassium Clavulanate Combination (3) · Metronidazole (3) · Tigecycline (3) · Tissue Plasminogen Activator (3) · dalbavancin (3) · remibrutinib (3) · secukinumab (3)
Novartis Pharmaceuticals (7) · Incyte Corporation (6) · MoonLake Immunotherapeutics AG (4) · UCB Biopharma SRL (4) · AbbVie (3) · AbbVie (prior sponsor, Abbott) (3) · Durata Therapeutics Inc., an affiliate of Allergan plc (3) · Melinta Therapeutics, Inc. (3) · Pfizer (3) · Post Graduate Institute of Medical Education and Research, Chandigarh (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Arpida AG (2) · Bayer (2) · Boehringer Ingelheim (2) · Children's Mercy Hospital Kansas City (2)
United States (55) · Germany (35) · Canada (34) · Spain (31) · Poland (30) · France (26) · Bulgaria (24) · Italy (22) · Argentina (19) · Belgium (19) · Greece (18) · Czechia (17) · Netherlands (17) · United Kingdom (17) · Australia (16)
David Melnick, MSD (2) · G. Ralph Corey, MD (2) · Lawrence Eichenfield, MD (2) · Michael Dunne, MD (2) · Prof Kristian Reich, M.D., Ph.D. (equ.) (2)
PMID 30597021, PMID 30716446, PMID 34741280, PMID 34905144, PMID 34922058, PMID 41248770, PMID 42482599, PMID 42525209, PMID 20695801, PMID 21115456, PMID 24897082, PMID 27370913, PMID 27518661, PMID 27585969, PMID 29358292, PMID 29380251, PMID 32965495, PMID 33599960, PMID 34976290, PMID 36746171, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 12145720, PMID 19036670, PMID 19036671, PMID 19220646, PMID 20346539, PMID 20663130, PMID 21115454, PMID 21115455, PMID 21896561, PMID 22265220, PMID 22581209, PMID 23180507, PMID 24010809, PMID 24439136, PMID 24797294, PMID 24897083, PMID 25294250
2023 (5), 2009 (2), 2018 (2), 2019 (2), 2025 (1)